Gamida Cell Ltd.(GMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GMDA Gamida Cell Ltd.

Delisted 11-21 16:00:00 EST

0.0327

+0.0000

0.00%

High0.0327	Low0.0327	Vol0.00
Open0.0327	D1 Closing0.0327	Amplitude0.00%
Mkt Cap5.04M	Tradable Cap4.64M	Total Shares154.05M
T/O0.00	T/O Rate0.00%	Tradable Shares142.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GMDA","market":"US","secType":"STK","nameCN":"Gamida Cell Ltd.","latestPrice":0.0327,"timestamp":1732222800000,"preClose":0.0327,"halted":4,"volume":0,"delay":0,"floatShares":142000000,"shares":154050953,"eps":-0.572433,"marketStatus":"Delisted","change":0,"latestTime":"11-21 16:00:00 EST","open":0.0327,"high":0.0327,"low":0.0327,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.572433,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732266000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1540526400000,"exchange":"NASDAQ","adjPreClose":0.0327,"volumeRatio":0},"requestUrl":"/m/hq/s/GMDA","defaultTab":"news","newsList":[{"id":"2453760334","title":"HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2453760334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453760334?lang=en_us&edition=fundamental","pubTime":"2024-07-22 21:12","pubTimestamp":1721653928,"startTime":"0","endTime":"0","summary":"HOOKIPA Pharma  said Monday it has appointed Malte Peters as chief executive and Terry Coelho as chief financial officer of the company, effective immediately.Peters will succeed Joern Aldag, while Coelho will succeed Reinhard Kandera, HOOKIPA added. Aldag and Kandera will be leaving the company and stepping down from its board.Peters most recently served as chief research and development officer at MorphoSys , while Coelho most recently was the CFO of Gamida Cell , the company said. They both will continue to serve on the HOOKIPA's board.Price: 6.43, Change: +0.01, Percent Change: +0.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","MOR","BK4139","HOOK","GMDA"],"gpt_icon":0},{"id":"2453641347","title":"Press Release: HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200","url":"https://stock-news.laohu8.com/highlight/detail?id=2453641347","media":"Dow Jones","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453641347?lang=en_us&edition=fundamental","pubTime":"2024-07-22 20:30","pubTimestamp":1721651400,"startTime":"0","endTime":"0","summary":"-- Director Dr. Malte Peters named Chief Executive Officer and Director. Terry Coelho named Executive Vice President and Chief Financial Officer. -- Company is conducting a review of its business operations and strategy to. determine best path to create shareholder value and realize the full. Dr. Jan van de Winkel, Chairman of the Board, said: \"HOOKIPA has entered a critical new phase of its development for HB-200. The Company has received PRIME designation from the European Medicines Agency, reached alignment on a clinical development strategy with the U.S. Food and Drug Administration with a path to potential accelerated approval, and announced the pivotal Phase 2/3 trial design. The Company also continues to advance its other development programs, including those in collaboration with Gilead, with the first person recently dosed in the Phase 1b clinical trial of HB-500 for the treatment of HIV.The Company also announced that Sean Cassidy will join its Board of Directors, Audit Commi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMDA","BK4505","NQmain","TQQQ","BK4139",".IXIC","SQQQ","BK4007","QID","QLD","MNQmain","HOOK","ARVN","PSQ"],"gpt_icon":1},{"id":"2444480714","title":"BRIEF-Gamida Cell Appoints Joe Wiley As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2444480714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444480714?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:18","pubTimestamp":1718716730,"startTime":"0","endTime":"0","summary":"June 18 (Reuters) -    * GAMIDA CELL LTD - NAMED JOE WILEY AS CEO, RORY NEALON AS CFO, AND SHEILA FRAME AS CHIEF COMMERCIAL OFFICERSource text for Eikon:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2434891916","title":"BRIEF-Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding","url":"https://stock-news.laohu8.com/highlight/detail?id=2434891916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2434891916?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:49","pubTimestamp":1715374146,"startTime":"0","endTime":"0","summary":"May 10  - Gamida Cell Ltd   :   * GAMIDA CELL LTD: ON MAY 8, DISTRICT COURT OF BEERSHEBA, ISRAEL ENTERED JUDGMENT IN RESTRUCTURING PROCEEDING   * GAMIDA CELL: JUDGMENT IN RESTRUCTURING PROCEEDING APPROVES DEBT ARRANGEMENT, OTHER TERMS & CONDITIONS OF CO'S RESTRUCTURING IN SUPPORT AGREEMENTSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2425999832","title":"XORTX Welcomes New Member to the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2425999832","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2425999832?lang=en_us&edition=fundamental","pubTime":"2024-04-08 11:30","pubTimestamp":1712547000,"startTime":"0","endTime":"0","summary":"CALGARY, Alberta, April  08, 2024  (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/08/2859085/0/en/XORTX-Welcomes-New-Member-to-the-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","XRTX","GMDA"],"gpt_icon":0},{"id":"2424697745","title":"BRIEF-Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive","url":"https://stock-news.laohu8.com/highlight/detail?id=2424697745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2424697745?lang=en_us&edition=fundamental","pubTime":"2024-04-01 22:29","pubTimestamp":1711981781,"startTime":"0","endTime":"0","summary":"April 1  - Aquestive Therapeutics Inc   :   * AQUESTIVE THERAPEUTICS STRENGTHENS BOARD OF DIRECTORS WITH EXPERIENCED BIOTECH EXECUTIVE   * AQUESTIVE THERAPEUTICS INC - BOARD OF DIRECTORS WILL NOW BE COMPRISED OF EIGHT DIRECTORSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EBS","GMDA","BK4583","BK4139","AQST","LENZ"],"gpt_icon":0},{"id":"2424134467","title":"Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive","url":"https://stock-news.laohu8.com/highlight/detail?id=2424134467","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2424134467?lang=en_us&edition=fundamental","pubTime":"2024-04-01 12:00","pubTimestamp":1711944000,"startTime":"0","endTime":"0","summary":"Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April  01, 2024  (GLOBE NEWSWIRE) -- Aquesti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/01/2855154/0/en/Aquestive-Therapeutics-Strengthens-Board-of-Directors-with-Experienced-Biotech-Executive.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","GMDA","AQST","BK4583","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2423462005","title":"BRIEF-Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2423462005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2423462005?lang=en_us&edition=fundamental","pubTime":"2024-03-29 21:45","pubTimestamp":1711719911,"startTime":"0","endTime":"0","summary":"March 29  - Gamida Cell Ltd   :   * GAMIDA CELL LTD - ON MARCH 28, RECEIVED NOTICE FROM NASDAQ NOTIFYING CO THAT IT DETERMINED CO’S ORDINARY SHARES WILL BE DELISTED FROM NASDAQ   * GAMIDA CELL LTD - NASDAQ STAFF FURTHER NOTIFIED CO THAT TRADING OF ORDINARY SHARES WILL BE SUSPENDED AT OPENING OF BUSINESS ON APRIL 8   * GAMIDA CELL LTD - DELISTING NOTICE ALSO INDICATED THAT CO MAY APPEAL NASDAQ’S DETERMINATION   * GAMIDA CELL LTD - CO DOES NOT INTEND TO APPEAL DETERMINATION AND, THEREFORE, IT IS EXPECTED THAT ORDINARY SHARES WILL BE DELISTED FROM NASDAQSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","QID","NDAQ","NQmain","GMDA","QQQ","LU2095319765.USD","LU2210149790.SGD","BK4139","TQQQ","LU2210150020.SGD","SQQQ","PSQ",".IXIC","BK4588","MNQmain","BK4585","QLD"],"gpt_icon":0},{"id":"2422122138","title":"Navigating the Compliance Maze: Gamida Cell’s Approach to Data Privacy and Security Amid Global Regulations","url":"https://stock-news.laohu8.com/highlight/detail?id=2422122138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422122138?lang=en_us&edition=fundamental","pubTime":"2024-03-28 14:01","pubTimestamp":1711605705,"startTime":"0","endTime":"0","summary":"Gamida Cell (GMDA) has disclosed a new risk, in the Regulation category. Gamida Cell navigates a complex landscape of stringent data privacy and se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/navigating-the-compliance-maze-gamida-cells-approach-to-data-privacy-and-security-amid-global-regulations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/navigating-the-compliance-maze-gamida-cells-approach-to-data-privacy-and-security-amid-global-regulations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2422318962","title":"Q4 2023 Gamida Cell Ltd Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2422318962","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422318962?lang=en_us&edition=fundamental","pubTime":"2024-03-28 11:19","pubTimestamp":1711595997,"startTime":"0","endTime":"0","summary":"Abigail Jenkins; President, Chief Executive Officer, Director; Gamida Cell Ltd. Terry Coelho; Chief Financial Officer; Gamida Cell Ltd. Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell's conference call for a business update and fourth quarter and full year 2023 financial results. My name is Daryl, and I'll be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell's request. Now I would like to introduce you to our conference host, Mike Kuczkowski of Gamida Cell Corporate Communications. Mike, please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2023-gamida-cell-ltd-031957878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GMDA"],"gpt_icon":0},{"id":"2422498729","title":"SMR, GCTS and GSIW among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422498729","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422498729?lang=en_us&edition=fundamental","pubTime":"2024-03-28 01:22","pubTimestamp":1711560136,"startTime":"0","endTime":"0","summary":"Gainers: GCT Semiconductor Holding  +421%. iBio  +198%. Cazoo Group Ltd  +66%. Stoke Therapeutics  +44%. Lixte Biotechnology Holdings  +44%. Ouster  +40%. Nuvation Bio  +38%. PAVmed  +36%. NuScale Power Corporation  +29%. Arrowroot Acquisition Corp  +28%.   Losers: Gamida Cell Ltd  -83%. Direct Digital Holdings  -40%. Wetouch Technology  -36%. Ryvyl  -34%. Forge Global Holdings  -25%. AEye  -23%. Bit Origin Ltd  -23%. Garden Stage Ltd  -24%. LuxUrban Hotels  -21%. OrganiGram Holdings  -20%.   More on Mid-day movers & stocks.  NuScale Power Corporation  Q3 2023 Earnings Call Transcript NuScale Power Corporation 2023 Q4 - Results - Earnings Call Presentation NuScale Power: Caught Between The High Seas Of SMR Commercialization And Financial Headwinds NuScale plunges as Wells Fargo cuts to Sell equivalent on 'misguided' enthusiasm NuScale soars to 52-week high as Canaccord sees less dilution than expected","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084533-smr-gcts-and-gsiw-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4148","BK4557","OUST","WETH","BK4212","PAVM","DRCT","BK4009","BK4205","BK4233","BK7083","OGI","BK4106","GSIW","BK4227","LIDR","BK4157","BK4023","BTOG","LIXT","STOK","BK4595","BK4122","GMDA","NUVB","BK4139","BK4082","SMR.AU","LUXH","BK4127","FRGE","BK7129","BK4182","RVYL","BK4214","GCTS","BK4568","SMR","BK4007","CZOO","ARRW","IBIO","BK4118"],"gpt_icon":0},{"id":"2422917009","title":"Crude Oil Edges Lower; PaySign Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2422917009","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422917009?lang=en_us&edition=fundamental","pubTime":"2024-03-28 00:00","pubTimestamp":1711555206,"startTime":"0","endTime":"0","summary":"U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday.\n\nThe Dow traded up 0.56% to 39,502.25 while the NASDAQ fell 0.08% to 16,302.03. The S&amp;P 500 also rose, gaining, 0.27% to 5,217.52.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37963375/crude-oil-edges-lower-paysign-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRDB","BK4139","SQQQ","VLD","QID","PSQ","NQmain","BK4161","QQQ","BK4009","LIXT","GMDA","BK4106","MNQmain","PAYS","TQQQ","BK4097","QLD","DRCT","BK4227"],"gpt_icon":0},{"id":"2422604249","title":"BRIEF-Gamida Cell To Cut Workforce By About 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422604249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422604249?lang=en_us&edition=fundamental","pubTime":"2024-03-27 19:45","pubTimestamp":1711539942,"startTime":"0","endTime":"0","summary":"March 27 (Reuters) - Gamida Cell Ltd   :   * GAMIDA CELL LTD - PLANS TO DOWNSIZE ITS CURRENT WORKFORCE BY APPROXIMATELY 25% BY END OF Q2 OF 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2422603889","title":"Gamida Cell Ltd. Announces Strategic Restructuring and Privatization","url":"https://stock-news.laohu8.com/highlight/detail?id=2422603889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422603889?lang=en_us&edition=fundamental","pubTime":"2024-03-27 19:42","pubTimestamp":1711539736,"startTime":"0","endTime":"0","summary":"An update from Gamida Cell Ltd (GMDA) is now available. Gamida Cell Ltd. has initiated a voluntary restructuring process with backing from Highbrid...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gamida-cell-ltd-announces-strategic-restructuring-and-privatization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gamida-cell-ltd-announces-strategic-restructuring-and-privatization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GMDA"],"gpt_icon":0},{"id":"2422896776","title":"Gamida Cell starts restructuring process supported by Highbridge Capital, stock down","url":"https://stock-news.laohu8.com/highlight/detail?id=2422896776","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422896776?lang=en_us&edition=fundamental","pubTime":"2024-03-27 19:36","pubTimestamp":1711539419,"startTime":"0","endTime":"0","summary":"Gamida Cell (NASDAQ:GMDA) has entered into a restructuring support agreement with certain funds managed by Highbridge Capital Management, and will become a private company, wholly owned by Highbridge ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084176-gamida-cell-starts-restructuring-process-supported-by-highbridge-capital-stock-down","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2422962889","title":"Gamida Cell GAAP EPS of $0.57 beats by $0.72, revenue of $1.78M beats by $0.72M","url":"https://stock-news.laohu8.com/highlight/detail?id=2422962889","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422962889?lang=en_us&edition=fundamental","pubTime":"2024-03-27 19:04","pubTimestamp":1711537461,"startTime":"0","endTime":"0","summary":"Gamida Cell press release  : Q4  GAAP EPS of $0.57  beats by $0.72.As of December 31, 2023, Gamida Cell had total cash and equivalents of $46.6 million compared to $64.7 million as of December 31, 2022.More on Gamida Cell  Gamida Cell stock jumps as company explores strategic alternatives Seeking Alpha’s Quant Rating on Gamida Cell Historical earnings data for Gamida Cell Financial information for Gamida Cell","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084164-gamida-cell-gaap-eps-of-057-beats-by-072-revenue-of-178m-beats-by-072m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","GMDA"],"gpt_icon":0},{"id":"2422497964","title":"Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2422497964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422497964?lang=en_us&edition=fundamental","pubTime":"2024-03-27 19:00","pubTimestamp":1711537200,"startTime":"0","endTime":"0","summary":"Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge . Gamida Cell to become a private company under ownership of Highbridge following Israeli court approval. Highbridge will convert $75 million of its existing unsecured convertible senior note into equity in the Company.The Company will receive $30 million of new capital from Highbridge on the effective date of the restructuring. This capital infusion, along with additional capital expected to be invested by Highbridge following the Company’s emergence, should position the Company to meet its goals around the commercialization of Omisirge.Gamida Cell will become a private company, wholly owned by Highbridge, and the Company’s outstanding ordinary shares are expected to be canceled.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fk0gTWh5WIVqUldOK8GiDQ--~B/aD02Mjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e135ff0daff055ce76b710b3cb097d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fk0gTWh5WIVqUldOK8GiDQ--~B/aD02Mjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e135ff0daff055ce76b710b3cb097d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gamida-cell-announces-commencement-restructuring-110000176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GMDA"],"gpt_icon":0},{"id":"2421971138","title":"Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2421971138","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2421971138?lang=en_us&edition=fundamental","pubTime":"2024-03-22 20:00","pubTimestamp":1711108800,"startTime":"0","endTime":"0","summary":"BOSTON, March 22, 2024  -- Gamida Cell Ltd. , a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year endedDecember 31, 2023and provide an update on the company onWednesday, March 27, 2024.Following the release, management will host a conference call and live webcast at8:30 AM Eastern Timeto discuss the financial results and provide a business update.A replay of the webcast will be available on the Company’s website. approximately two hours after the event, for approximately 30 days.Gamida Cellis a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide  technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge, an FDA-approved nicotinamide modifie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fk0gTWh5WIVqUldOK8GiDQ--~B/aD02Mjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e135ff0daff055ce76b710b3cb097d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fk0gTWh5WIVqUldOK8GiDQ--~B/aD02Mjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e135ff0daff055ce76b710b3cb097d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gamida-cell-report-fourth-quarter-120000352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GMDA","BK4139"],"gpt_icon":0},{"id":"2419805381","title":"Gamida Cell Revises Executive Compensation Amid Financial Constraints","url":"https://stock-news.laohu8.com/highlight/detail?id=2419805381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2419805381?lang=en_us&edition=fundamental","pubTime":"2024-03-16 04:22","pubTimestamp":1710534163,"startTime":"0","endTime":"0","summary":"Gamida Cell Ltd (GMDA) has issued an update. Gamida Cell Ltd. has revised the employment agreements with its executive officers, including the CEO,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gamida-cell-revises-executive-compensation-amid-financial-constraints?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gamida-cell-revises-executive-compensation-amid-financial-constraints?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GMDA"],"gpt_icon":0},{"id":"2414332820","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2414332820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2414332820?lang=en_us&edition=fundamental","pubTime":"2024-02-27 19:00","pubTimestamp":1709031600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Bank of Nova Scotia                              1Q      1.19   5:30 AM. Bumble Inc. Class A                             4Q       .12   4:05 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXON","NGM","AZO","AGO","DDD","OCN","CLNE.AU","JLL.AU","PNW","BSY","ALEC","EYE.AU","LMND","PAR.AU","MOND","ATEC.AU","OCN.AU","FLYW","SJM","BYND","AESI","OVV","CMLS","OSUR","LGND","ICFI","ACHC","KIND","M","NNOX","PARR","BMBL","CRI","MYGN","APLS","MASI","MGNX","ALC.AU","PNW.AU","AHCO","JLL","MRUS","ARQT","BEAM","CHE","GMDA","TILE","BECN","ASTH","LMAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gamida-cell.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.892},{"period":"ytd","weight":-0.9208}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.148003},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.012908},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.279964},{"month":4,"riseRate":0.333333,"avgChangeRate":0.080575},{"month":5,"riseRate":0.4,"avgChangeRate":0.063306},{"month":6,"riseRate":0,"avgChangeRate":-0.150827},{"month":7,"riseRate":0,"avgChangeRate":-0.180953},{"month":8,"riseRate":0.4,"avgChangeRate":0.075826},{"month":9,"riseRate":0.2,"avgChangeRate":-0.108316},{"month":10,"riseRate":0.8,"avgChangeRate":0.040304},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004806},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.036686}],"exchange":"NASDAQ","name":"Gamida Cell Ltd.","nameEN":"Gamida Cell Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gamida Cell Ltd.(GMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gamida Cell Ltd.(GMDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gamida Cell Ltd.,GMDA,Gamida Cell Ltd.股票,Gamida Cell Ltd.股票老虎,Gamida Cell Ltd.股票老虎国际,Gamida Cell Ltd.行情,Gamida Cell Ltd.股票行情,Gamida Cell Ltd.股价,Gamida Cell Ltd.股市,Gamida Cell Ltd.股票价格,Gamida Cell Ltd.股票交易,Gamida Cell Ltd.股票购买,Gamida Cell Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gamida Cell Ltd.(GMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gamida Cell Ltd.(GMDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction